DISCOVERIES (ISSN 2359-7232), 2014, January-March

CITATION:

Friedman MT, Avadhani V, Gilmore S, Madrigal E. Blood Transfusion in the 21st Century. Discoveries 2014, Jan-Mar; 2(1): e11. DOI: 10.15190/d.2014.3;

Submitted: March 11, 2014; Published after revision:March 31, 2014

GO BACK to 2014, January-March issue
GO BACK to DISCOVERIES

Blood Transfusion in the 21st Century

Mark T. Friedman (1,*), Vaidehi Avadhani (1), Sandra Gilmore (2) and
Emilio Madrigal (1)

Affiliation:
(1) Department of Pathology, Blood Bank and Transfusion Services (2) Blood Management, Bloodless Medicine and Surgery, Mount Sinai Health System, St. Luke’s, Roosevelt, and Beth Israel Hospitals, Icahn School of Medicine at Mount Sinai, New York, NY, USA

*Correspondence should be addressed to: Mark T. Friedman, DO, Mount Sinai Roosevelt Hospital, Medical Director of Blood Bank and Transfusion Service, 1000 Tenth Avenue, New York, NY 10019. Phone: 212-523-7242; Fax: 212-523-6394; Email: markfriedman@chpnet.org

Abstract

Blood transfusion is a common procedure in the hospital setting, and the safety of the blood supply has been vastly improved over the past few decades largely due to improvements in screening for viral transmissible diseases, especially human immunodeficiency virus (HIV) and viral hepatitis. However, more recent efforts to improve blood safety have focused on non-transmissible disease risks such as transfusion-related acute lung injury (TRALI), non-viral transmissible diseases such as bacterial contamination of blood products (especially platelet components which are stored at room temperature) and Chagas disease (a parasitic disease caused by Trypanosoma cruzi), and prion transmissible agents (e.g., variant Creutzfeldt-Jakob disease, also known as the agent of mad cow disease) as well as more recently-recognized transmissible viral disease risks such as West Nile virus. Appropriate blood utilization has also come under more intense scrutiny in recent times due to healthcare costs and the recognition that many blood transfusions are given under circumstances in which the benefit to the patients is unclear and may be potentially harmful due to the above risks as well as the emerging concept that blood transfusions may cause long-term damage to the immune system resulting in worse patient morbidity and mortality outcomes. Toward that end, accreditation agencies such as the Joint Commission and the American Association of Blood Banks (AABB) are advocating for healthcare organizations to implement appropriate patient blood management strategies. This review will examine these issues along with newer blood safety technological innovations and further highlight contributing studies from our institutions.

Access full text of the manuscript here: See full text (pdf)

References

1. US Department of Health and Human Services. The 2009 national blood collection and utilization survey report. Washington, DC: US Department of Health and Human Services, Office of the Assistant Secretary for Health, 2011. Available from: http://www.hhs.gov/ash/ bloodsafety/2009nbcus.pdf
2. Hogue CW, Goodnough LT, Monk TG. Perioperative myocardial episodes are related to hematocrit level in patients undergoing radical prostatectomy. Transfusion 1998; 38: 924-31. PMID: 9767742.
3. Wu W-C, Rathore MPH, Wang Y, et al. Blood transfusion in elderly patients with acute myocardial infarction. N Engl J Med. 2001;345:1230-6. PMID: 11680442.
4. Kramer AH, Zygun DA. Anemia and red blood cell transfusion in neurocritical care. Crit Care 2009; 13: R89. PMID: 19519893.
5. Hébert PC, Wells G, Blajchman MA, et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. N Engl J Med. 1999;340(6):409-17. PMID: 9971864.
6. Carson JL, Terrin ML, Magaziner J, et al. Transfusion trigger trial for functional outcomes in cardiovascular patients undergoing surgical hip fracture repair (FOCUS). Transfusion 2006; 46(12): 2192-206. PMID: 17176334.
7. Lacroix J, Hébert PC, Hutchison JS, et al. Transfusion strategies for patients in pediatric intensive care units. N Engl J Med. 2007;356(16): 1609-19. PMID: 17442904.
8. Villanueva C, Colomo A, Bosch A, et al.Transfusion strategies for acute upper gastrointestinal bleeding. N Engl J Med. 2013;368:11-21[Erratum, N Engl J Med. 2013;368:2341.] PMID: 23281973.
9. Carson JL, Grossman BJ, Kleinman S, et al. Red blood cell transfusion: a clinical practice guideline from the AABB. Ann Intern Med. 2012;157(1):49-58. PMID: 22751760
10. Napolitano LM, Kurek S, Luchette FA, et al. Clinical practice guideline: Red blood cell transfusion in adult trauma and critical care for the American College of Critical Care Medicine of the Society of Critical Care Medicine and the Eastern Association for the Surgery of Trauma Practice Management Workgroup. Crit Care Med. 2009;37(12):3124-57. PMID: 19773646.
11. Verlicchi F, Desalvo F, Zanotti G, et al. Red cell transfusion in orthopaedic surgery: a benchmark study performed combining data from different sources. Blood Transfus. 2011. PMID: 21627924.
12. National Heart, Lung and Blood Institute. What are the risks of a blood transfusion? http://www.nhlbi.nih.gov/health/health-opics/topics/bt/risks.html Accessed on March 5, 2014.
13. U.S. Food and Drug Administration. Guidance for Industry: Assessing Donor Suitability and Blood and Blood Product Safety in Cases of Known or Suspected West Nile Virus Infection. June 2005. http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Blood/ucm074111.htm Accessed on March 7, 2014.
14. U.S. Food and Drug Administration. Draft Guidance for Industry: Use of Serological Tests to Reduce the Risk of Transmission of Trypanosoma cruzi Infection in Whole Blood and Blood Components for Transfusion and Human Cells, Tissues, and Cellular and Tissue-Based Products. March 2009. http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Tissue/ucm125678.htm Accessed on March 7, 2014.
15. Centers for Disease Control and Prevention. Bacterial contamination of platelets. http://www.cdc.gov/bloodsafety/bbp/bacterial-contamination-of-platelets.html Accessed on March 7, 2014.
16. Linden JV, Wong SJ, Chu FK, et al. Transfusion associated transmission of babesiosis in New York State. Transfusion 2000;40:285-9. PMID: 10738027.
17. Llewelyn CA, Hewitt PE, Knight RS, et al. Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. Lancet 2004; 363: 417-21. PMID: 14962520.
18. Murphy EL, David Connor J, McEvoy P, et al. Estimating blood donor loss due to the variant CJD travel deferral. Transfusion. 2004;44(5):645-50. PMID: 15104643.
19. Féray C, Pawlotsky JM, Roque-Afonso AM, et al. Should we screen blood products for hepatitis E virus RNA? The Lancet. 2014;383:218. PMID: 24439737.
20 AABB. TRALI Risk Reduction Requirements in the 29th Edition of BBTS Standards. https://www.aabb.org/sa/standards/Pages/trali-requirements-bbts-standards.aspx Accessed on March 5, 2014.
21. Goldman M, Webert KE, Arnold DM, et al. Proceedings of a consensus conference: towards an understanding of TRALI. Transfus Med Rev. 2005;19(1):2-31. PMID: 15830325.
22. Strobel E. Hemolytic transfusion reactions. Transfus Med Hemother. Oct 2008; 35(5):346–353. PMID: 21512623.
23. Linden JV, Pisciotto PT. Transfusion-associated graft-versus-host disease and blood irradiation. Transfus Med Rev. 1992;6:116–123. PMID: 1591488.
24. Fierce Homeland Security. Security of radiological sources at medical facilities needs improvement, says GAO. http://www.fiercehomelandsecurity.com/story/security-radiological-sources-medical-acilities-needs-improvement-says-gao/2012-09-13 Accessed on March 6, 2014.
25. Branch DR. Solving the dilemma of prevention of red cell alloimmunization. Immunotherapy. 2012; 9:903-905. PMID: 23046234.
26. AABB. National Hemovigilance Program Launches to Track Adverse Events Associated with Blood Transfusion. http://www.aabb.org/pressroom/pressreleases/Pages/pr100218.aspx February 18, 2010. Accessed on March 7, 2014.
27. Bolton-Maggs PHB, Cohen H. Serious Hazards of Transfusion (SHOT) haemovigilance and progress is improving transfusion safety. Br J Haematol. 2013;163:303-314. PMID: 24032719.28.
28. U.S. Food and Drug Administration. Guidance for Industry: Notifying FDA of Fatalities Related to Blood Collection or Transfusion. http://www.fda.gov/biologicsbloodvaccines/guidancecomplianceregulatory information/guidances/blood/ucm074947.htm September 2003. Accessed on March 26, 2014.
29. New York State Department of Health. Transfusion/Blood Bank-related Incident Report. http://www.wadsworth.org/labcert/blood_tissue/forms/doh3336.pdf Accessed on March 26, 2014.
30. New Jersey Department of Health. Transfusion Reaction Report. http://www.state.nj.us/health/ forms/cl-44.dot Accessed on March 26, 2014.31.ICCBBA. What is ISBT 128? http://www.iccbba.org/home/isbt-128-basics/what-is-isbt-128 Accessed on March 1, 2014.
32. French Agency for the Safety of Health Products. Analysis of the risk of transmission of variant of Creutzfeldt-Jakob disease by health products and by tissues and fluids of human origin; update of findings of ad hoc group report of December 2000. Feb 2004. http://ansm.sante.fr/var/ansm_site/storage/original/application/2906328b3b0e08c665a7c7b0e5c42020.pdf Accessed on March 5, 2014.
33. Blumberg N, Heal JM. Blood transfusion immunomodulation. The silent epidemic. Arch Pathol Lab Med. 1998;122:117-8. PMID: 9499352.
34. Koch CG, Li L, Sessler DI, et al. Duration of red-cell storage and complications after cardiac surgery. N Engl J Med. 2008; 358: 1229-39. PMID: 18354101.
35. Arinsburg SA, Skerrett DL, Friedman MT, Cushing M. A survey to assess transfusion medicine education needs for clinicians. Transfus Med. 2012;22:44-51. PMID: 22141339.
36. Friedman MT. Blood transfusion practices: a little consistency please. Blood Transfus. 2011;9:362-5. PMID: 21627918
37. AABB. Patient blood management. http://www.aabb.org/resources/bct/pbm/Pages/default.aspx Accessed on March 3, 2014.
38. The Joint Commission. New patient blood managment program certification proposed by Joint Commission. http://www.supportingsaferhealthcare.com/2013/08/new-patient-blood-management-certification-program-proposed-by-joint-commission/ Accessed on March 3, 2014.
39. The Joint Commission. Implementation Guide for The JointCommission Patient Blood Management Performance Measures.Oak Brook Terrace, IL: The Joint Commission; 2011:14-17. Available at: http://www.jointcommission.org/assets/1/6/pbm_implementation_guide_20110624.pdf. Accessed on March 3, 2014.
40. Friedman MT, Ebrahim A. Adequacy of physician documentation of red blood cell transfusion and correlation with assessment of transfusion appropriateness. Arch Pathol Lab Med. 2006; 130:474-479. PMID: 16594741.
41. De Leon EM, Szallasi A. "Transfusion indication RBC (PBM-02)": gap analysis of a Joint Commission Patient Blood Management Performance Measure at a community hospital. Blood Transfus. 2014; 12 Suppl 1: s187-90:187-190. PMID: 23149139.
42. Friedman M, Arja W, Batra R, Daniel S, et al. Informed consent for blood transfusion: What Do Medicine Residents Tell? What Do Patients Understand? Am J Clin Pathol. 2012;138:559-565. PMID: 23010711.
43. Institute of Medicine Committee on Quality of Health Care in America. Crossing the Quality Chasm: A New Health System for the 21st Century. Washington, DC: National Academies Press; 2001.
44. Spahn DR. Blood substitutes. Artificial oxygen carriers: Perfluorocarbon emulsions. Crit Care. 1999;3:R93-R97. PMID: 11094488.
45. Dong Q, Stowell CP. Blood substitutes. What they are and how they might be used. Am J Clin Pathol. 2002;118(Suppl 1):S71-S80. PMID: 14569814.
46. Remy B, Deby-Dupont G, Lamy M. Red blood cell substitutes: fluorocarbon emulsions and haemoglobin solutions. British Medical Bulletin. 1999;55:277-298. PMID: 10695091.
47. Alayash AI. Blood substitutes: why haven’t we been more successful? Trends in Biotechnology. 2014;4:177-185. PMID: 24630491.
48. Kim HW, Greenburg AG. Toward 21st century blood component replacement therapeutics: artificial oxygen carriers, platelet substitutes, recombinant clotting factors, and others. Artif Cells Blood Substit Immobil Biotechnol. 2006;34:537-550. PMID: 17090427.
49. Cerus Press Release Details. Cerus and Grifols to collaborate on INTERCEPT Red Cell kit development. Cerus Corporation, 6/2/2009. http://www.cerus.com/Investors/Press-Releases/Press-Release-Details/2009/Cerus-and-Grifols-to-Collaborate-on-INTERCEPT-Red-Cell-Kit-Development/default.aspx Accessed on March 28, 2014.
50. Hellstern P, Solheim BG. The use of solvent/ detergent treatment in pathogen reduction of plasma. Transfuse Med Hemother. 2011;38:65-70. PMID: 21779207.
51. U.S. Food and Drug Administration. Safety Alert: PLAS+SD (Pooled Plasma, (Human) Solvent Detergent Treated). March 29, 2002. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm155086.htm Accessed on March 28, 2014.
52. Lusher JM. Hemophilia: from plasma to recombinant factors. American Society of Hematology.http://www.hematology.org/publications/50-years-in-hematology/4737.aspx Accessed on March 27, 2014.
53. Novo Nordisk. NovoSeven RT prescribing information.http://www.novo-pi.com/novosevenrt. pdf Accessed on March 6, 2014.
54. Mayer SA, Brun NC, Begtrup K, et al. Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med. 2005;352:777-785. PMID: 15728810.
55. Mayer SA, Brun NC, Begtrup K. Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med. 2008; 358: 2127-2137. PMID: 18480205.
56. Menitove JE, Leach Bennett J, Tomasulo P, Katz LM. How safe is safe enough, who decides and how? From a zero-risk paradigm to a risk-based decision making. Transfusion. 2014;54:753-757. PMID: 24617628.

GO BACK to 2014, January-March issue
GO BACK to DISCOVERIES
MEET OUR EDITORIAL BOARD
SUBMIT A MANUSCRIPT

Email us at info@discoveriesjournals.org if you have any questions.